<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221015056180N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-11-02</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>effect of potassium permanganate solution on diabetic foot</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of topical potassium permanganate 5% solution on foot ulcers in diabetic patients – a randomisad controled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>22</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66315</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Type of randomization: in this research, in order to allocate patients to intervention and control groups, a resticted randomization approach will be used in a parallel way and random allocation rule.
To generate random numbers, online randomization will be used at the following address
http://www.graphpad.com/quickcalcs/index.cfm
Allocation concealment method: Random allocation concealment method will be used for concealment. At the time of registration of eligible patients for the study, using identical sealed envelopes with random sequence, the patient will be a candidate to receive one of two types of treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in the intervention group will wash the wound with soap and water every day and then use  potassium permanganate 5% solution topically. This solution is bought by the researcher from the pharmacy. And every week, the patient will be given the necessary amount to consume for a week. To prepare a  solution of potassium permanganate 5%, the pharmacist combines 5 grams of it with 100 cc of distilled water. (This will be done under standard conditions and by the pharmacist). Patients are instructed to apply the solution with cotton soaked in potassium permanganate to all parts of their diabetic foot ulcer, so that the whole ulcer is covered with the solution and the healthy parts of the skin are not covered with the solution and not to wash the wound with water after that. Intervention 2: Control group: The control group is a candidate to receive the standard treatment of diabetic foot ulcer. The standard treatment of diabetic foot ulcer is as follows: removal and transfer of pressure from the area of diabetic foot ulcer, daily washing of the ulcer with mild soap and water, checking the condition of the ulcer daily.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After deidentifying people, all the data obtained from the research, including the demographic information of the samples, clinical information and the results of the intervention can be shared.

When:
It is possible to access the results after six months from the publication of the results

To whom:
Researchers in academic centers and scientific research centers

Conditions:
In order to data comparison in similar studies, the researchers of academic centers and scientific research centers have the possibility to receive data and re-analyze it if they comply with the principles of ethics in research.

Where to obtain:
Burn and Regenerative Medicine Research Center, Guilan University of Medical Sciences, Rasht, Iran
Address: Burn Research Center and Regenerative Medicine, Velayat Hospital (3rd floor), Namjo St., Rasht.
Contact phone: +98-1333368540
Dr. Mohammad Reza Mobayen
Email address: Mmobayen@gums.ac.ir

How to obtain:
Researchers should send a written request to receive data to the relevant email address. The review of the documents and the application is done within two to four weeks. Then, if the necessary conditions are met, the data will be provided to the researchers by the research center.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr Afrooz Haghdoost</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Burn and Regenerative Medicine Research center, Khanali Zade St, Namjoo St, Velayat hospital,</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713191</zip>
        <telephone>00931333368540</telephone>
        <email>haghdoost.afrooz@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Afrooz Haghdoost</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Burn and Regenerative Medicine Research center, Khanali Zade St, Namjoo St, Velayat hospital,</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4193713191</zip>
        <telephone>+98 13 3336 8540</telephone>
        <email>haghdoost.afrooz@yahoo.com</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Outpatient referral
Patients with type 2 diabetes
Diabetic foot ulcer with Wagner score 1 or 2
Presence of chronic neuropathic and non-ischemic diabetic foot ulcer that has been present for at least 3 months
Patients in the age range of 18 to 65 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The presence of ischemia symptoms in the lower limbs and ankle-brachial index and toe-brachial index (ABI, TBI) less than 0.7
Advanced wound infection</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>ICDE-10</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>ﻣﺮﺑﻮط ﺑﻪ ﻋﻮارض ﻧﻮروﻟﻮژﻳﻚ و ﺳﺎﻳﺮ ﻋﻮارض دﻳﺎﺑﺖ</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in the intervention group will wash the wound with soap and water every day and then use  potassium permanganate 5% solution topically. This solution is bought by the researcher from the pharmacy. And every week, the patient will be given the necessary amount to consume for a week. To prepare a  solution of potassium permanganate 5%, the pharmacist combines 5 grams of it with 100 cc of distilled water. (This will be done under standard conditions and by the pharmacist). Patients are instructed to apply the solution with cotton soaked in potassium permanganate to all parts of their diabetic foot ulcer, so that the whole ulcer is covered with the solution and the healthy parts of the skin are not covered with the solution and not to wash the wound with water after that.</i_keyword>
      <i_keyword>Control group: The control group is a candidate to receive the standard treatment of diabetic foot ulcer. The standard treatment of diabetic foot ulcer is as follows: removal and transfer of pressure from the area of diabetic foot ulcer, daily washing of the ulcer with mild soap and water, checking the condition of the ulcer daily.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Local infection of diabetic foot ulcer. Timepoint: Investigation of wound infection at the beginning of the study and then on days 7, 14 and 21. Method of measurement: Based on the examination and determining the Wagner score of diabetic foot ulcer.</prim_outcome>
      <prim_outcome>Size of diabetic foot ulcer. Timepoint: Measurement of diabetic foot ulcer at the beginning of the study and then on days 7, 14 and 21. Method of measurement: With examination and caliper device.</prim_outcome>
      <prim_outcome>Granulation tissue formation. Timepoint: Examination of granulation tissue formation at the beginning of the study and then on days 7, 14 and 21. Method of measurement: Based on examination of diabetic foot ulcer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The duration of complete healing of diabetic foot ulcer. Timepoint: At the beginning of the study and then on days 7, 14 and 21. Method of measurement: Based on the examination of the attending physician.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-08-17</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Deputy of research and technology of Guilan university of medical sciences, Siyadati St, Namju St Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
